三阴性乳腺癌靶向治疗策略

目的:总结近期国内外三阴性乳腺癌的靶向治疗研究进展。方法:应用Medline、Pub Med、Web of science、CNKI数据库,以"三阴性乳腺癌、基底样乳腺癌和靶向治疗"为关键词,搜索近期发表的相关临床研究。共纳入文献30篇。结果:大量临床试验发现,靶向表皮生长因子受体(EGFR)抑制药西妥昔单抗(单克隆抗体)能明显提高TNBC患者的总反应率(ORR)、无进展生存期(PFS)、总生存期(OS)或临床获益(CB);血管内皮生长因子(VEGF)抑制药贝伐珠单抗(单克隆抗体)不能延长患者OS,但能显著延长MBC/ABC患者的PFS和ORR,索拉非尼(小分子抑制剂)能改善TNBC患者的PFS;腺苷核糖聚合酶(PARP)抑制药olaparib,能使BRCA1/2基因突变的TNBC患者获益。结论:随着对TNBC生物学行为的深入研究,新的靶点不断被发现、新的靶向药物陆续面市,使TNBC治疗策略更完善。

Targeted treatment strategies of three negative breast cancer

OBJECTIVE: To summarize recent targeted treatment strategies of TNBC of domestic and oversea.METHODS: "triple-negative breast cancer,basal-like breast cancer and targeted therapy" as the Keywords,recently published clinical trials were searched from databases of Medline,Pub Med,Web of science,CNKI.Thirty papers were finally reviewed.RESULTS: Large clinical trials found that: cetuximab,one of epidermal growth factor receptor(EGFR) inhabitors,can greatly improve ORR,PFS,OS and CB of TNBC patients.As one of Vascular endothelial growth factor(VEGF) inhabitors,Avastin can significantly extend MBC/ABC patients’ ORR and PFS and sorafenib(small molecule inhibitors) can prolong the PFS of TNBC patients.TNBC patients can get benefit from PARP inhabitor: olaparib.CONCLUSION: As advanced study of biological behavior of TNBC,new targets and drugs are discovered,so more TNBC patients will get greater benefit from better targeted treatment strategies.